Literature DB >> 24811013

Mast cell activation disorders.

Cem Akin1.   

Abstract

Disorders associated with mast cell activation range from relatively common IgE-mediated disease and chronic urticaria to rarer conditions such as mastocytosis or monoclonal mast cell activation disorder. Mast cell activation disorders can be mechanistically classified into primary (associated with abnormal production of mast cells that carry pathologic markers of clonality), secondary (normal mast cells activated in reaction to a microenvironmental trigger), and idiopathic (no etiology is found). Clinical presentations, diagnostic criteria as well as general principles of a stepwise therapy approach are discussed.
Copyright © 2014 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diagnosis; Mast cell activation syndromes; Mast cells; Mastocytosis; Treatment; Tryptase c-kit

Mesh:

Substances:

Year:  2014        PMID: 24811013     DOI: 10.1016/j.jaip.2014.03.007

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  13 in total

1.  A 60-year-old woman with recurrent episodes of flushing, urticaria, and angioedema.

Authors:  Sheenal V Patel; James L Baldwin
Journal:  Allergy Asthma Proc       Date:  2015 May-Jun       Impact factor: 2.587

Review 2.  Mast Cell Activation Syndrome.

Authors:  Marianne Frieri
Journal:  Clin Rev Allergy Immunol       Date:  2018-06       Impact factor: 8.667

Review 3.  Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders?

Authors:  Theoharis C Theoharides; Irene Tsilioni; Huali Ren
Journal:  Expert Rev Clin Immunol       Date:  2019-04-22       Impact factor: 4.473

4.  Global microRNA expression is essential for murine mast cell development in vivo.

Authors:  Sun Young Oh; Stephanie Brandal; Reuben Kapur; Zhou Zhu; Clifford M Takemoto
Journal:  Exp Hematol       Date:  2014-09-06       Impact factor: 3.084

5.  Genomic and transcriptomic comparison of allergen and silver nanoparticle-induced mast cell degranulation reveals novel non-immunoglobulin E mediated mechanisms.

Authors:  Monica Johnson; Nasser Alsaleh; Ryan P Mendoza; Indushekhar Persaud; Alison K Bauer; Laura Saba; Jared M Brown
Journal:  PLoS One       Date:  2018-03-22       Impact factor: 3.240

6.  Management of a Parturient with Mast Cell Activation Syndrome: An Anesthesiologist's Experience.

Authors:  Sangeeta Kumaraswami; Gabriel Farkas
Journal:  Case Rep Anesthesiol       Date:  2018-05-22

7.  Developing Rat Bone Marrow Derived Mast Cells by the Splenic Cells Culture Supernatant of Rat and Mouse.

Authors:  Saeede Amani; Rasoul Shahrooz; Ali Karimi; Zahra Bakhtiari; Esmaeil Mortaz
Journal:  Tanaffos       Date:  2019-02

Review 8.  Intestinal Mucosal Mast Cells: Key Modulators of Barrier Function and Homeostasis.

Authors:  Mercé Albert-Bayo; Irene Paracuellos; Ana M González-Castro; Amanda Rodríguez-Urrutia; María J Rodríguez-Lagunas; Carmen Alonso-Cotoner; Javier Santos; María Vicario
Journal:  Cells       Date:  2019-02-08       Impact factor: 6.600

9.  Second messenger Ap4A polymerizes target protein HINT1 to transduce signals in FcεRI-activated mast cells.

Authors:  Jing Yu; Zaizhou Liu; Yuanyuan Liang; Feng Luo; Jie Zhang; Cuiping Tian; Alex Motzik; Mengmeng Zheng; Jingwu Kang; Guisheng Zhong; Cong Liu; Pengfei Fang; Min Guo; Ehud Razin; Jing Wang
Journal:  Nat Commun       Date:  2019-10-11       Impact factor: 14.919

Review 10.  Adrenal insufficiency is a contraindication for omalizumab therapy in mast cell activation disease: risk for serum sickness.

Authors:  G J Molderings; F L Dumoulin; J Homann; B Sido; J Textor; M Mücke; G J Qagish; R Barion; M Raithel; D Klingmüller; V S Schäfer; H J Hertfelder; D Berdel; G Tridente; L B Weinstock; L B Afrin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-05-06       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.